Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.38
VRTX's Cash to Debt is ranked lower than
75% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 41.89 vs. VRTX: 1.38 )
Ranked among companies with meaningful Cash to Debt only.
VRTX' s Cash to Debt Range Over the Past 10 Years
Min: 0.92  Med: 2.11 Max: 26.61
Current: 1.38
0.92
26.61
Equity to Asset 0.39
VRTX's Equity to Asset is ranked lower than
78% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VRTX: 0.39 )
Ranked among companies with meaningful Equity to Asset only.
VRTX' s Equity to Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.46 Max: 0.95
Current: 0.39
-0.02
0.95
F-Score: 5
Z-Score: 5.51
M-Score: -2.35
WACC vs ROIC
15.29%
-9.09%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -5.02
VRTX's Operating margin (%) is ranked higher than
69% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -88.05 vs. VRTX: -5.02 )
Ranked among companies with meaningful Operating margin (%) only.
VRTX' s Operating margin (%) Range Over the Past 10 Years
Min: -602.63  Med: -112.58 Max: 8.07
Current: -5.02
-602.63
8.07
Net-margin (%) -13.17
VRTX's Net-margin (%) is ranked higher than
65% of the 735 Companies
in the Global Biotechnology industry.

( Industry Median: -76.71 vs. VRTX: -13.17 )
Ranked among companies with meaningful Net-margin (%) only.
VRTX' s Net-margin (%) Range Over the Past 10 Years
Min: -630.27  Med: -111.44 Max: 2.1
Current: -13.17
-630.27
2.1
ROE (%) -22.68
VRTX's ROE (%) is ranked higher than
59% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -33.76 vs. VRTX: -22.68 )
Ranked among companies with meaningful ROE (%) only.
VRTX' s ROE (%) Range Over the Past 10 Years
Min: -180.27  Med: -58.14 Max: 4.58
Current: -22.68
-180.27
4.58
ROA (%) -8.69
VRTX's ROA (%) is ranked higher than
69% of the 958 Companies
in the Global Biotechnology industry.

( Industry Median: -30.04 vs. VRTX: -8.69 )
Ranked among companies with meaningful ROA (%) only.
VRTX' s ROA (%) Range Over the Past 10 Years
Min: -58.14  Med: -29.94 Max: 1.51
Current: -8.69
-58.14
1.51
ROC (Joel Greenblatt) (%) -12.01
VRTX's ROC (Joel Greenblatt) (%) is ranked higher than
74% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. VRTX: -12.01 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRTX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1092.55  Med: -251.29 Max: 110.77
Current: -12.01
-1092.55
110.77
Revenue Growth (3Y)(%) -15.50
VRTX's Revenue Growth (3Y)(%) is ranked lower than
70% of the 471 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. VRTX: -15.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRTX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -32.5  Med: 8.1 Max: 129.4
Current: -15.5
-32.5
129.4
GuruFocus has detected 1 Warning Sign with Vertex Pharmaceuticals Inc $VRTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» VRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

VRTX Guru Trades in Q1 2016

Leucadia National 3,300 sh (New)
Steven Cohen 838,700 sh (New)
David Carlson 230,000 sh (New)
Samuel Isaly 162,000 sh (New)
Jim Simons 112,617 sh (+83.66%)
John Paulson 61,500 sh (+32.54%)
Vanguard Health Care Fund 12,668,241 sh (+28.91%)
Pioneer Investments 876,770 sh (+14.26%)
Andreas Halvorsen Sold Out
Paul Tudor Jones Sold Out
Ken Fisher 5,155 sh (-7.00%)
Joel Greenblatt 5,046 sh (-57.21%)
» More
Q2 2016

VRTX Guru Trades in Q2 2016

Manning & Napier Advisors, Inc 126,990 sh (New)
George Soros 6,300 sh (New)
Joel Greenblatt 108,656 sh (+2053.31%)
Pioneer Investments 1,111,794 sh (+26.81%)
David Carlson 270,000 sh (+17.39%)
Vanguard Health Care Fund 12,914,741 sh (+1.95%)
Samuel Isaly 528,100 sh (+225.99%)
Leucadia National Sold Out
John Paulson Sold Out
Steven Cohen Sold Out
Ken Fisher 5,112 sh (-0.83%)
Jim Simons 60,517 sh (-46.26%)
» More
Q3 2016

VRTX Guru Trades in Q3 2016

Jeremy Grantham 50,300 sh (New)
John Burbank 2,830 sh (New)
Manning & Napier Advisors, Inc 142,540 sh (+12.25%)
Pioneer Investments 1,231,092 sh (+10.73%)
Ken Fisher 5,168 sh (+1.10%)
David Carlson 270,000 sh (unchged)
Jeremy Grantham 100,000 sh (unchged)
Vanguard Health Care Fund 12,914,741 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Joel Greenblatt 66,716 sh (-38.60%)
Samuel Isaly 269,807 sh (-48.91%)
» More
Q4 2016

VRTX Guru Trades in Q4 2016

Spiros Segalas 1,905,121 sh (+74.17%)
Ken Fisher 5,168 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with VRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:INCY, OTCPK:ALIOY, NAS:BMRN, OTCPK:UCBJY, NAS:GRFS, NAS:ALXN, OTCPK:GMXAY, OTCPK:NVZMY, NAS:ALKS, NAS:SGEN, NAS:TSRO, NAS:JAZZ, NAS:UTHR, NAS:IONS, OTCPK:SBMFF, NAS:EXEL, NAS:ARIA, NAS:ACAD, NAS:TECH, NAS:ALNY » details
Traded in other countries:VX1.Germany, VRTX.Mexico, VRTX.Switzerland, 0QZU.UK,
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets.

Vertex Pharmaceuticals Inc was incorporated in 1989. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. It is focused on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and early-stage development programs. The Company has marketed KALYDECO (ivacaftor) since it was approved in 2012 for the treatment of certain patients with CF and is seeking approval to market lumacaftor in combination with ivacaftor in order to increase the number of patients with CF who would be eligible for treatment with the Company's drugs. It is engaged in a number of other research and early-stage development programs, including programs in the areas of oncology and neurology. The Company's three products are INCIVE (telaprevir), which is approved for the treatment of patients with genotype 1 hepatitis C virus, or HCV, infection; and KALYDECO (ivacaftor), which is approved in the United States for the treatment of patients six years of age and older with cystic fibrosis, or CF, who genetic mutation in their cystic fibrosis transmembrane conductance regulator, or CFTR, gene, which is referred to as the G551D mutation. INCIVEK is approved in the United States and Canada for the treatment of adults with genotype 1 hepatitis C virus, or HCV, infection and ORKAMBI. The Company began marketing ORKAMBI (lumacaftor in combination with ivacaftor) in the United States in 2015. In November 2015, the European Commission approved ORKAMBI, and the Company is seeking country-by-country reimbursement for ORKAMBI in Europe. As the Company markets and sells its approved products and advances its drug candidates through clinical development toward commercialization, it continues to build and maintain its supply chain and quality assurance resources. It faces competition based on the safety and efficacy of its products and drug candidates, the timing and scope of regulatory approvals, the availability and cost of supply, marketing and sales capabilities, reimbursement coverage, price, patent protection and other factors. Its registered trademarks include Vertex, KALYDECO and INCIVEK. The research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, safety monitoring, record keeping, promotion, advertising, distribution and marketing of its products and drug candidates are subject to extensive regulation by United States and foreign governmental authorities.

Ratios

vs
industry
vs
history
Forward P/E 32.26
VRTX's Forward P/E is ranked lower than
77% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. VRTX: 32.26 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 19.75
VRTX's P/B is ranked lower than
93% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. VRTX: 19.75 )
Ranked among companies with meaningful P/B only.
VRTX' s P/B Range Over the Past 10 Years
Min: 5.78  Med: 13.66 Max: 37.6
Current: 19.75
5.78
37.6
P/S 11.93
VRTX's P/S is ranked lower than
52% of the 683 Companies
in the Global Biotechnology industry.

( Industry Median: 10.85 vs. VRTX: 11.93 )
Ranked among companies with meaningful P/S only.
VRTX' s P/S Range Over the Past 10 Years
Min: 4.38  Med: 19.32 Max: 77.75
Current: 11.93
4.38
77.75
POCF 164.72
VRTX's POCF is ranked lower than
93% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 19.90 vs. VRTX: 164.72 )
Ranked among companies with meaningful POCF only.
VRTX' s POCF Range Over the Past 10 Years
Min: 11.43  Med: 52.88 Max: 236.03
Current: 164.72
11.43
236.03
Current Ratio 2.08
VRTX's Current Ratio is ranked lower than
73% of the 947 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. VRTX: 2.08 )
Ranked among companies with meaningful Current Ratio only.
VRTX' s Current Ratio Range Over the Past 10 Years
Min: 1.73  Med: 4.27 Max: 30.95
Current: 2.08
1.73
30.95
Quick Ratio 1.98
VRTX's Quick Ratio is ranked lower than
71% of the 946 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. VRTX: 1.98 )
Ranked among companies with meaningful Quick Ratio only.
VRTX' s Quick Ratio Range Over the Past 10 Years
Min: 1.62  Med: 4.27 Max: 30.95
Current: 1.98
1.62
30.95
Days Inventory 105.38
VRTX's Days Inventory is ranked higher than
59% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 127.64 vs. VRTX: 105.38 )
Ranked among companies with meaningful Days Inventory only.
VRTX' s Days Inventory Range Over the Past 10 Years
Min: 62.49  Med: 129.06 Max: 254.87
Current: 105.38
62.49
254.87
Days Sales Outstanding 40.03
VRTX's Days Sales Outstanding is ranked higher than
69% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 61.83 vs. VRTX: 40.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.75  Med: 47.58 Max: 106.15
Current: 40.03
25.75
106.15
Days Payable 87.10
VRTX's Days Payable is ranked higher than
65% of the 400 Companies
in the Global Biotechnology industry.

( Industry Median: 58.15 vs. VRTX: 87.10 )
Ranked among companies with meaningful Days Payable only.
VRTX' s Days Payable Range Over the Past 10 Years
Min: 87.1  Med: 443.5 Max: 1204.41
Current: 87.1
87.1
1204.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.30
VRTX's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 550 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. VRTX: -4.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
VRTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -18.1  Med: -11.6 Max: -2.5
Current: -4.3
-18.1
-2.5

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 29.39
VRTX's Price/Tangible Book is ranked lower than
94% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. VRTX: 29.39 )
Ranked among companies with meaningful Price/Tangible Book only.
VRTX' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.13  Med: 12.51 Max: 120.7
Current: 29.39
2.13
120.7
Price/Median PS Value 0.62
VRTX's Price/Median PS Value is ranked higher than
74% of the 593 Companies
in the Global Biotechnology industry.

( Industry Median: 0.94 vs. VRTX: 0.62 )
Ranked among companies with meaningful Price/Median PS Value only.
VRTX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.26  Med: 1 Max: 3.78
Current: 0.62
0.26
3.78
Earnings Yield (Greenblatt) (%) -0.40
VRTX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 924 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. VRTX: -0.40 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRTX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -0.4  Med: 2.8 Max: 5.4
Current: -0.4
-0.4
5.4

More Statistics

Revenue (TTM) (Mil) $1,661
EPS (TTM) $ -0.90
Beta1.80
Short Percentage of Float2.32%
52-Week Range $71.46 - 103.73
Shares Outstanding (Mil)248.03

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 1,689 2,182 2,781 3,515
EPS ($) 0.71 2.16 3.79 5.85
EPS w/o NRI ($) 0.71 2.16 3.79 5.85
EPS Growth Rate
(3Y to 5Y Estimate)
82.00%
Dividends Per Share ($)

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)